Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 10/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464857 | 0.86 | HRH4 (0.50) | SOS1HTR3AHRH4HRH3 | |
| SCHEMBL12225078 | 0.86 | SOS1 (0.41) | SOS1HRH4 | |
| SCHEMBL2533033 | 0.86 | SOS1 (0.35) | SOS1HTR3A | |
| Hydrochloric Acid SCHEMBL2466905 | 0.85 | SOS1 (0.35) | SOS1HTR3A | |
| SCHEMBL2465334 | 0.84 | CYP1A2 (0.40) | SOS1HTR3A | |
| SCHEMBL2532585 | 0.77 | HRH4 (0.42) | SOS1HRH4HRH3 | |
| SCHEMBL12224910 | 0.77 | HRH4 (0.42) | SOS1HRH4HRH3 | |
| SCHEMBL404537 | 0.76 | HRH4 (0.49) | SOS1HTR3AHRH4HRH3 | |
| SCHEMBL2530224 | 0.73 | HRH4 (0.40) | SOS1HTR3AHRH4HRH3 | |
| SCHEMBL12225096 | 0.73 | HRH4 (0.46) | SOS1HTR3AHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | SOS1 3564/4885HTR3A 153/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.